Cancer Prices Make Comparative Effectiveness Trials Difficult, Researchers Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Experts note that the high price tags for novel oncology products is discouraging to third-party comparative effectiveness research, which is one of the few things that could actually check the steady climb of cancer costs.